Contribute Try STAT+ Today

The U.K. government and the pharmaceutical industry have reached a tentative agreement to widen access to medicines and encourage innovation that involves spending caps on brand-name medicines and faster cost-effectiveness assessments, among other things.

The voluntary deal calls for the National Health Service to adopt newer medicines faster for five unidentified therapeutic categories. Drug makers agreed to an annual 2 percent cap on the growth in sales of branded medicines to the NHS. And the National Institute for Health and Care Excellence will speed its value appraisals so that all medicines are assessed as quickly as cancer treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy